215 related articles for article (PubMed ID: 22457522)
1. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.
Fisher R; van Zyl GU; Travers SA; Kosakovsky Pond SL; Engelbrech S; Murrell B; Scheffler K; Smith D
J Virol; 2012 Jun; 86(11):6231-7. PubMed ID: 22457522
[TBL] [Abstract][Full Text] [Related]
2. It is time to consider third-line options in antiretroviral-experienced paediatric patients?
Zyl GU; Rabie H; Nuttall JJ; Cotton MF
J Int AIDS Soc; 2011 Nov; 14():55. PubMed ID: 22085598
[TBL] [Abstract][Full Text] [Related]
3. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
Taylor BS; Hunt G; Abrams EJ; Coovadia A; Meyers T; Sherman G; Strehlau R; Morris L; Kuhn L
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):945-56. PubMed ID: 21345162
[TBL] [Abstract][Full Text] [Related]
4. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Lataillade M; Chiarella J; Yang R; DeGrosky M; Uy J; Seekins D; Simen B; St John E; Moreno E; Kozal M
PLoS One; 2012; 7(2):e30118. PubMed ID: 22355307
[TBL] [Abstract][Full Text] [Related]
5. Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.
Obasa AE; Ambikan AT; Gupta S; Neogi U; Jacobs GB
BMC Infect Dis; 2021 Feb; 21(1):214. PubMed ID: 33632139
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
7. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
8. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
[TBL] [Abstract][Full Text] [Related]
9. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
[TBL] [Abstract][Full Text] [Related]
10. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
11. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of PI resistance in patients failing second-line ART in Vietnam.
Thao VP; Quang VM; Day JN; Chinh NT; Shikuma CM; Farrar J; Van Vinh Chau N; Thwaites GE; Dunstan SJ; Le T
J Antimicrob Chemother; 2016 Mar; 71(3):762-74. PubMed ID: 26661398
[TBL] [Abstract][Full Text] [Related]
13. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.
Barber TJ; Harrison L; Asboe D; Williams I; Kirk S; Gilson R; Bansi L; Pillay D; Dunn D;
J Antimicrob Chemother; 2012 Apr; 67(4):995-1000. PubMed ID: 22258921
[TBL] [Abstract][Full Text] [Related]
14. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
16. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
Thompson JA; Kityo C; Dunn D; Hoppe A; Ndashimye E; Hakim J; Kambugu A; van Oosterhout JJ; Arribas J; Mugyenyi P; Walker AS; Paton NI;
Clin Infect Dis; 2019 Mar; 68(7):1184-1192. PubMed ID: 30060027
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
Hoppe A; Giuliano M; Lugemwa A; Thompson JA; Floridia M; Walker AS; Senoga I; Abwola MC; Pirillo MF; Kityo CM; Arenas-Pinto A; Paton NI;
Antivir Ther; 2018; 23(2):191-195. PubMed ID: 29021409
[TBL] [Abstract][Full Text] [Related]
19. Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.
Dunn DT; Stöhr W; Arenas-Pinto A; Tostevin A; Mbisa JL; Paton NI;
J Clin Virol; 2018 Apr; 101():63-65. PubMed ID: 29428459
[TBL] [Abstract][Full Text] [Related]
20. Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART.
Hermans LE; Steegen K; Ter Heine R; Schuurman R; Tempelman HA; Moraba R; van Maarseveen E; Nijhuis M; Pillay T; Legg-E'Silva D; Snyman T; Schapiro JM; Burger DM; Carmona S; Wensing AM
J Int AIDS Soc; 2020 Jun; 23(6):e25501. PubMed ID: 32515898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
